EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis

Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav

Indian Journal of Rheumatology · 2025-09 · 20 (3) · 284-297

DOI: 10.1177/09733698251316343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Rheumatology, online erschienen am 22.04.2025. Verfasst von Krishna. S Upadhye und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to traditional disease-modifying antirheumatic drugs (DMARDs) and other JAK inhibitors. Authors conducted a systematic search of PubMed, Scopus and Google Scholar to identify relevant studies, including phase I, II, and III clinical trials. We extracted and synthesised data on efficacy end points (ACR20, ACR50, and ACR70), safety profiles, and long-term outcomes. We performed comparative analyses with traditional DMARDs and other JAK inhibitors. Filgotinib demonstrates high efficacy in RA management, with ACR20 response rates ranging from 70% to 80%, ACR50 from 40% to 50%, and ACR70 from 20% to 30%. It significantly reduces disease activity (as measured by DAS28-CRP) and improves physical function (as indicated by Health Assessment Questionnaire Disability Index [HAQ-DI] scores). Compared to traditional DMARDs, filgotinib offers superior efficacy and a favourable safety profile. In comparison to other JAK inhibitors, filgotinib’s selective JAK1 inhibition contributes to a similar or improved safety profile while maintaining high efficacy. Long-term data confirm its sustained benefits and manageable safety profile. Filgotinib is a promising treatment option for RA, offering significant benefits. Clinical trials have observed improvements in disease activity and quality of life. Its selective JAK1 inhibition and favourable safety profile make it a competitive alternative to both traditional DMARDs and other JAK inhibitors. Ongoing research into personalised medicine and emerging therapies will further define filgotinib’s role in RA management.

Zitieren

APA

Upadhye, K. S., Tayade, P., Patidar, H., & Yadav, N. (2025). Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis. Indian Journal of Rheumatology, 20(3), 284-297. https://doi.org/10.1177/09733698251316343

Vancouver

Upadhye KS, Tayade P, Patidar H, Yadav N. Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis. Indian Journal of Rheumatology. 2025;20(3):284-297. doi:10.1177/09733698251316343

BibTeX
@article{Upadhye2025,
  author = {Upadhye, Krishna. S and Tayade, Paritosh and Patidar, Hariom and Yadav, Narendra},
  title = {Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis},
  journal = {Indian Journal of Rheumatology},
  year = {2025},
  volume = {20},
  number = {3},
  pages = {284--297},
  doi = {10.1177/09733698251316343}
}
Kostenlos starten →